FDA greenlights Marius' oral hypogonadism pill; VBL Therapeutics makes cuts to its workforce
The FDA has approved Marius’ testosterone replacement treatment for adult males with hypogonadism, or testosterone deficiency.
The oral drug, to be marketed as Kyzatrex, will …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
